Current perspective on actinic keratosis: a review

British Journal of Dermatology

Volumn 177, Issue 2, 2017, Pages 350-358

  Siegel, J A ^a,b   Korgavkar, K ^a,b   Weinstock, M A ^a,b  

^a PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; INGENOL MEBUTATE; LIQUID NITROGEN; RETINOIC ACID; DERMATOLOGICAL AGENT;

ACTINIC KERATOSIS; CHEMOPROPHYLAXIS; CRYOTHERAPY; CURETTAGE; DISEASE CLASSIFICATION; DISEASE COURSE; ESTHETICS; HUMAN; LONG TERM EXPOSURE; MALIGNANT TRANSFORMATION; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN ABRASION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; UNITED STATES; ADULT; AGE; AGED; COST OF ILLNESS; DISEASE EXACERBATION; FEMALE; MALE; MIDDLE AGED; SEX FACTOR;

ADULT; AGE FACTORS; AGED; COST OF ILLNESS; DERMATOLOGIC AGENTS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 84994226533     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14852     Document Type: Review

References (64)

1. Bickers DR, Lim HW, Margolis D et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55:490–500.
2. Weinstock MA, Bingham SF, Cole GW et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA Topical Tretinoin Chemoprevention (VATTC) trial. Arch Dermatol 2001; 137:1055–8.
3. Lee KC, Lew R, Weinstock MA. Improvement in precision of counting actinic keratoses. Br J Dermatol 2014; 170:188–91.
4. Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol 2004; 43:638–42.
5. Criscione VD, Weinstock MA, Naylor MF et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs topical tretinoin chemoprevention trial. Cancer 2009; 115:2523–30.
6. Lambert SR, Mladkova N, Gulati A et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Br J Cancer 2014; 110:520–9.
7. Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156:8–12.
8. Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol 2013; 68:S2–9.
9. Ulrich M, Krueger-Corcoran D, Roewert-Huber J et al. Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology 2010; 220:15–24.
10. Kaur RR, Alikhan A, Maibach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J Dermatol Treat 2010; 21:267–71.
11. Kopera D, Kerl H. Visualization and treatment of subclinical actinic keratosis with topical imiquimod 5% cream: an observational study. BioMed Res Int 2014; 2014:135916.
12. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:8–10.
13. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol 2007; 46:895–904.
14. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147–51.
15. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 2000; 115:273–7.
16. Marks R, Foley P, Goodman G. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115:649–55.
17. Venna S, Lee D. Clinical recognition of actinic keratoses in a high risk population: how good are we? Arch Dermatol 2005; 141:507–9.
18. Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics 2009; 27:451–64.
19. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 2012; 68:S11–19.
20. Quaedvlieg PJ, Tirsi E, Thissen MR et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16:335–9.
21. Werner RN, Sammain A, Erdmann R et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169:502–18.
22. Harvey I, Frankel S, Marks R et al. Non-melanoma skin cancer and solar keratoses I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74:1302–7.
23. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1:795–7.
24. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol 2000; 42:S11–17.
25. Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12:186–92.
26. Fernández-Figueras MT, Carrato C, Sáenz X et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015; 29:991–7.
27. Bowman PH, Ratz JL, Knoepp TG et al. Basosquamous carcinoma. Dermatol Surg 2003; 29:830–2.
28. de Faria JL. Basal cell carcinoma of the skin with areas of squamous cell carcinoma: a basosquamous cell carcinoma? J Clin Pathol 1985; 38:1273–7.
29. Berhane T, Halliday GM, Cooke B et al. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002; 146:810–15.
30. Chen GJ, Feldman SR, Williford PM et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg 2005; 31:43–47.
31. Flohil SC, van der Leest RJT, Dowlatshahi EA et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol 2013; 133:1971–8.
32. Frazer IH. The actinic keratosis virome: can we prevent squamous cell carcinoma with a vaccine? Curr Probl Dermatol 2015; 46:28–35.
33. Lebwohl MG, Rosen T, Stockfleth E. The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic options. Cutis 2010; 86:S1–11.
34. Jacobs LC, Liu F, Pardo LM et al. IRF4, MC1R and TYR genes are risk factors for actinic keratosis independent of skin color. Hum Mol Genet 2015; 24:3296–303.
35. Weinstock MA, Lee KC, Chren MM, Marcolivio K; VATTC Trial Group. Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) Trial. J Am Acad Dermatol 2009; 6:207–15.
36. Weinstock MA, Lee KC. Prospective quality of life impact of actinic keratoses: observations from the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Acta Derm Venereol 2011; 91:101–2.
37. The Lewin Group, Inc. (2005) The burden of skin diseases 2004. Available at: http://www.sidnet.org/files/Burden%20of%20Skin%20Diseases%202004%20Final%20Sept%2005.pdf (last accessed 25 July 2016).
38. Warino L, Tusa M, Camacho F et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg 2006; 32:1045–9.
39. Naylor MF, Boyd A, Smith DW et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995; 131:170–5.
40. Pomerantz H, Hogan D, Eilers D et al. Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 2015; 151:952–60.
41. Gupta AK, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013; 169:250–9.
42. Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS ONE 2014; 9:1–10.
43. Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12:CD004415.
44. Weinstock MA, Bingham SF, Digiovanna JJ et al. Veterans Affairs Topical Tretinoin Chemoprevention Trial Group. Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012; 132:1583–90.
45. Thai KE, Fergin P, Freeman M et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004; 43:687–92.
46. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol 2006; 5:133–9.
47. Jorizzo JL, Markowitz O, Lebwohl MG et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010; 9:1101–8.
48. Lanoue J, Do T, Goldenberg G. Therapies for actinic keratosis with a focus on cosmetic outcomes. Cutis 2015; 96:165–72.
49. Esmann S, Jemec GBE. Patients' perceptions of topical treatments of actinic keratosis. J Dermatolog Treat 2014; 25:375–9.
50. Goldberg LH, Joseph AK, Tschen JA. Proliferative actinic keratosis. Int J Dermatol 1994; 33:341–5.
51. Chen SC, Hill ND, Veledar E et al. Reliability of quantification measures of actinic keratosis. Br J Dermatol 2013; 169:1219–22.
52. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131:455–64.
53. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86:25–28.
54. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol 1997; 36:650–3.
55. Goldenberg G, Perl M. Actinic keratosis update on field therapy. J Clin Aesthet Dermatol 2014; 28:28–31.
56. Kuflik EG. Cryosurgery updated. J Am Acad Dermatol 1994; 31:925–44.
57. Perez MI, Bank DE, Silvers D. Skin resurfacing of the face with the Erbium:YAG laser. Dermatol Surg 1998; 24:653–9.
58. Hantash BM, Stewart DB, Cooper ZA et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol 2006; 142:976–82.
59. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135:1177–83.
60. Coleman WP 3rd, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 1996; 22:17–22.
61. Costa C, Scalvenzi M, Ayala F et al. How to treat actinic keratosis? An update J Dermatol Case Rep 2015; 2:29–35.
62. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol 2013; 68:S39–48.
63. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of severe adverse events with application of Picato (ingenol Mebutate) gel for skin condition; requires label changes, 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm459142.htm (last accessed 25 July 2016).
64. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5:156–9.